Literature DB >> 2156925

Constitutive production of human interleukin for DA cells/leukemia inhibitory factor by human tumor cell lines derived from various tissues.

H Gascan1, I Anegón, V Praloran, J Naulet, A Godard, J P Soulillou, Y Jacques.   

Abstract

The cytokine HILDA (human IL for DA cells)/LIF (leukemia inhibitory factor), previously reported to trigger the proliferation of the DA1.a cell line was purified to homogeneity from the culture supernatant of the 5637 bladder carcinoma cell line by using a four step procedure, including cationic exchange chromatography at pH 6, Con A affinity chromatography, reverse phase HPLC, and gel filtration HPLC. The purified radiolabeled protein was analyzed in SDS-PAGE and a single band with a molecular mass of 43 kDa was revealed. The iodinated material was then tested in a radioreceptor assay using the M1 cell line as a second target cell line. The binding of the natural 125I hormone was abrogated in a dose dependent and specific fashion by either natural and rHILDA. The limit of signal detection of displacement for the radiolabeled ligand by unlabeled sample was found to be 0.05 ng/ml. The proliferative DA1.a assay and the M1 radioreceptor assay were used to analyze the HILDA content of 17 human tumor cell line culture supernatants, and 12 among them were spontaneously secreting a detectable level of LIF. The secreted amount of HILDA was largely enhanced by treating the cell line with 30 to 80 nM PMA; in these conditions a 10 to 20x increase in the detected amount was observed. The specificity of the detected signal was reinforced by analyzing the mRNA expression of HILDA in the tumor cell lines. The secreting cell lines were found to express various forms of LIF transcripts with a major specie at 3.8 kb.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156925

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.

Authors:  Danielle N Seto; Susan C Kandarian; Robert W Jackman
Journal:  J Biol Chem       Date:  2015-06-19       Impact factor: 5.157

2.  Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study.

Authors:  G Kontogeorgos; H Patralexis; A Tran; K Kovacs; S Melmed
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

3.  "Differentiation Induction" culture of human leukemic myeloid cells stimulates high production of macrophage differentiation inducing factor.

Authors:  T Abe; M Ohno; T Sato; M Murakami; M Kajiki; R Kodaira
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

4.  High circulating leukaemia inhibitory factor (LIF) in patients with giant cell arteritis: independent regulation of LIF and IL-6 under corticosteroid therapy.

Authors:  J C Lecron; P Roblot; S Chevalier; F Morel; E Alderman; J Gombert; H Gascan
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

5.  Induction of cytokine expression by leukemia inhibitory factor.

Authors:  P M Villiger; Y Geng; M Lotz
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

6.  Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids.

Authors:  P Waring; K Wycherley; D Cary; N Nicola; D Metcalf
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

7.  Expression of leukemia inhibitory factor in craniopharyngioma.

Authors:  A Tran; K Kovacs; L Stefaneanu; G Kontogeorgos; B W Scheithauer; S Melmed
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

8.  Pathophysiology and treatment of inflammatory anorexia in chronic disease.

Authors:  Theodore P Braun; Daniel L Marks
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

9.  Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.

Authors:  Susan C Kandarian; Rachel L Nosacka; Andrea E Delitto; Andrew R Judge; Sarah M Judge; John D Ganey; Jesse D Moreira; Robert W Jackman
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-09-30       Impact factor: 12.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.